Compare Lantheus Holdings, Inc. with Similar Stocks
Dashboard
1
Strong Long Term Fundamental Strength with a 125.40% CAGR growth in Operating Profits
- The company is Net-Debt Free
- The company has been able to generate a Return on Equity (avg) of 21.34% signifying high profitability per unit of shareholders funds
2
Flat results in Mar 26
3
With ROCE of 23.89%, it has a attractive valuation with a 3.86 Enterprise value to Capital Employed
4
High Institutional Holdings at 100%
Stock DNA
Pharmaceuticals & Biotechnology
USD 4,811 Million (Small Cap)
20.00
NA
0.00%
0.20
22.08%
4.41
Revenue and Profits:
Net Sales:
377 Million
(Quarterly Results - Mar 2026)
Net Profit:
118 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
28.27%
0%
28.27%
6 Months
58.17%
0%
58.17%
1 Year
32.43%
0%
32.43%
2 Years
24.88%
0%
24.88%
3 Years
16.9%
0%
16.9%
4 Years
69.94%
0%
69.94%
5 Years
315.75%
0%
315.75%
Lantheus Holdings, Inc. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
35.35%
EBIT Growth (5y)
125.40%
EBIT to Interest (avg)
12.46
Debt to EBITDA (avg)
1.37
Net Debt to Equity (avg)
-0.32
Sales to Capital Employed (avg)
0.91
Tax Ratio
28.61%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
28.81%
ROE (avg)
21.34%
Valuation key factors
Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
4.41
EV to EBIT
16.14
EV to EBITDA
13.18
EV to Capital Employed
3.86
EV to Sales
3.26
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
23.89%
ROE (Latest)
22.08%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
Bullish
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Mar 2026
Shareholding Compare (%holding) 
Majority shareholders
Domestic Funds
Domestic Funds
Held in 129 Schemes (62.22%)
Foreign Institutions
Held by 209 Foreign Institutions (21.33%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Mar'26 - YoY
Mar'26
Mar'25
Change(%)
Net Sales
377.30
372.80
1.21%
Operating Profit (PBDIT) excl Other Income
104.00
115.70
-10.11%
Interest
4.90
4.80
2.08%
Exceptional Items
14.90
-14.90
200.00%
Consolidate Net Profit
118.40
72.90
62.41%
Operating Profit Margin (Excl OI)
215.50%
273.80%
-5.83%
USD in Million.
Net Sales
YoY Growth in quarter ended Mar 2026 is 1.21% vs 0.76% in Mar 2025
Consolidated Net Profit
YoY Growth in quarter ended Mar 2026 is 62.41% vs -44.39% in Mar 2025
Annual Results Snapshot (Consolidated) - Dec'25
Dec'25
Dec'24
Change(%)
Net Sales
1,541.60
1,533.90
0.50%
Operating Profit (PBDIT) excl Other Income
382.30
510.50
-25.11%
Interest
19.70
19.70
Exceptional Items
-5.30
-40.90
87.04%
Consolidate Net Profit
233.60
312.40
-25.22%
Operating Profit Margin (Excl OI)
202.50%
290.70%
-8.82%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2025 is 0.50% vs 18.32% in Dec 2024
Consolidated Net Profit
YoY Growth in year ended Dec 2025 is -25.22% vs -4.38% in Dec 2024
About Lantheus Holdings, Inc. 
Lantheus Holdings, Inc.
Pharmaceuticals & Biotechnology
Lantheus Holdings, Inc. is engaged in the development, manufacture and commercialization of diagnostic medical imaging agents and products that assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its imaging agents and products are used across a range of imaging modalities, including echocardiography and nuclear imaging. It operates in two segments: U.S. Segment and International Segment. The U.S. Segment produces and markets its medical imaging agents and products throughout the United States. In the United States, it sells its products to radiopharmacies, integrated delivery networks, hospitals, clinics and group practices. The International Segment operations consist of production and distribution activities in Puerto Rico and direct distribution activities in Canada. Its portfolio of nine commercial products is diversified across a range of imaging modalities. Its products include an ultrasound contrast agent and medical radiopharmaceuticals.
Company Coordinates 
Company Details
331 Treble Cove Rd , NORTH BILLERICA MA : 01862-2849
Registrar Details






